PubMed:29305532
Annnotations
c_corpus
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-5 | PR:Q5S006 | denotes | LRRK2 |
| T2 | 0-5 | PR:000003033 | denotes | LRRK2 |
| T3 | 0-5 | PR:Q5S007 | denotes | LRRK2 |
| T7 | 97-103 | Q9N297 | denotes | 5-HT1A |
| T8 | 97-103 | Q0EAB6 | denotes | 5-HT1A |
| T9 | 97-103 | PR:000001161 | denotes | 5-HT1A |
| T10 | 97-103 | Q6XXX9 | denotes | 5-HT1A |
| T11 | 97-103 | Q9N296 | denotes | 5-HT1A |
| T12 | 97-103 | Q6XXY0 | denotes | 5-HT1A |
| T13 | 97-103 | P19327 | denotes | 5-HT1A |
| T14 | 97-103 | Q9N298 | denotes | 5-HT1A |
| T15 | 97-103 | PR:P19327 | denotes | 5-HT1A |
| T16 | 97-103 | Q64264 | denotes | 5-HT1A |
| T17 | 97-103 | Q98998 | denotes | 5-HT1A |
| T18 | 97-103 | PR:P28285 | denotes | 5-HT1A |
| T19 | 97-103 | P08908 | denotes | 5-HT1A |
| T20 | 97-112 | D044282 | denotes | 5-HT1A Receptor |
| T21 | 99-102 | CVCL_4W51 | denotes | HT1 |
| T24 | 129-133 | D051379 | denotes | Mice |
| T26 | 129-133 | 10095 | denotes | Mice |
| T23 | 129-133 | PR:000005054 | denotes | Mice |
| T25 | 129-133 | O89094 | denotes | Mice |
| T28 | 152-159 | 6308 | denotes | leucine |
| T29 | 152-159 | SO:0001437 | denotes | leucine |
| T27 | 152-159 | CHEBI:15603 | denotes | leucine |
| T30 | 152-159 | D007930 | denotes | leucine |
| T31 | 152-159 | CHEBI:25017 | denotes | leucine |
| T32 | 152-159 | D007930 | denotes | leucine |
| T33 | 165-171 | SO:0001068 | denotes | repeat |
| T34 | 182-187 | PR:Q5S006 | denotes | LRRK2 |
| T35 | 182-187 | PR:000003033 | denotes | LRRK2 |
| T36 | 182-187 | PR:Q5S007 | denotes | LRRK2 |
| T37 | 189-193 | SO:0000704 | denotes | gene |
| T42 | 231-250 | D010300 | denotes | Parkinson's disease |
| T43 | 231-250 | D010300 | denotes | Parkinson's disease |
| T46 | 279-284 | PR:Q5S006 | denotes | LRRK2 |
| T47 | 279-284 | PR:000003033 | denotes | LRRK2 |
| T48 | 279-284 | PR:Q5S007 | denotes | LRRK2 |
| T49 | 285-293 | SO:0000109 | denotes | mutation |
| T50 | 457-462 | PR:Q5S006 | denotes | LRRK2 |
| T51 | 457-462 | PR:000003033 | denotes | LRRK2 |
| T52 | 457-462 | PR:Q5S007 | denotes | LRRK2 |
| T53 | 463-471 | SO:0000109 | denotes | mutation |
| T54 | 556-566 | UBERON:0004704 | denotes | depression |
| T55 | 641-651 | SO:0000781 | denotes | transgenic |
| T56 | 657-661 | PR:000005054 | denotes | mice |
| T58 | 657-661 | O89094 | denotes | mice |
| T57 | 657-661 | D051379 | denotes | mice |
| T59 | 657-661 | 10095 | denotes | mice |
| T60 | 673-678 | D006801 | denotes | human |
| T61 | 686-691 | PR:Q5S006 | denotes | LRRK2 |
| T62 | 686-691 | PR:000003033 | denotes | LRRK2 |
| T63 | 686-691 | PR:Q5S007 | denotes | LRRK2 |
| T64 | 776-780 | PR:000022285 | denotes | maze |
| T65 | 776-780 | PR:P0AE72 | denotes | maze |
| T66 | 776-780 | PR:P96621 | denotes | maze |
| T67 | 776-780 | PR:Q2FWI7 | denotes | maze |
| T68 | 782-789 | 10159 | denotes | sucrose |
| T69 | 782-789 | D013395 | denotes | sucrose |
| T70 | 782-789 | CHEBI:17992 | denotes | sucrose |
| T71 | 782-789 | D013395 | denotes | sucrose |
| T72 | 814-822 | GO:0036268 | denotes | swimming |
| T73 | 833-837 | UBERON:4000164 | denotes | tail |
| T74 | 833-837 | UBERON:2001058 | denotes | tail |
| T75 | 833-837 | UBERON:0002415 | denotes | tail |
| T76 | 877-887 | UBERON:0004704 | denotes | depression |
| T77 | 943-947 | PR:000005054 | denotes | mice |
| T79 | 943-947 | O89094 | denotes | mice |
| T78 | 943-947 | D051379 | denotes | mice |
| T80 | 943-947 | 10095 | denotes | mice |
| T81 | 1044-1048 | UBERON:0003101 | denotes | male |
| T82 | 1044-1048 | CHEBI:30780 | denotes | male |
| T83 | 1053-1059 | UBERON:0003100 | denotes | female |
| T84 | 1060-1064 | PR:000005054 | denotes | mice |
| T86 | 1060-1064 | O89094 | denotes | mice |
| T85 | 1060-1064 | D051379 | denotes | mice |
| T87 | 1060-1064 | 10095 | denotes | mice |
| T88 | 1152-1156 | PR:000005054 | denotes | mice |
| T90 | 1152-1156 | O89094 | denotes | mice |
| T89 | 1152-1156 | D051379 | denotes | mice |
| T91 | 1152-1156 | 10095 | denotes | mice |
| T92 | 1189-1198 | CHEBI:28790 | denotes | serotonin |
| T93 | 1189-1198 | D012701 | denotes | serotonin |
| T94 | 1189-1198 | CHEBI:350546 | denotes | serotonin |
| T95 | 1189-1198 | D012701 | denotes | serotonin |
| T96 | 1241-1252 | UBERON:0002421 | denotes | hippocampus |
| T97 | 1241-1252 | UBERON:0001954 | denotes | hippocampus |
| T98 | 1241-1252 | UBERON:0002961 | denotes | hippocampus |
| T99 | 1259-1263 | PR:000005054 | denotes | mice |
| T101 | 1259-1263 | O89094 | denotes | mice |
| T100 | 1259-1263 | D051379 | denotes | mice |
| T102 | 1259-1263 | 10095 | denotes | mice |
| T106 | 1314-1320 | Q9N297 | denotes | 5-HT1A |
| T107 | 1314-1320 | Q0EAB6 | denotes | 5-HT1A |
| T108 | 1314-1320 | PR:000001161 | denotes | 5-HT1A |
| T109 | 1314-1320 | Q6XXX9 | denotes | 5-HT1A |
| T110 | 1314-1320 | Q9N296 | denotes | 5-HT1A |
| T111 | 1314-1320 | Q6XXY0 | denotes | 5-HT1A |
| T112 | 1314-1320 | P19327 | denotes | 5-HT1A |
| T113 | 1314-1320 | Q9N298 | denotes | 5-HT1A |
| T114 | 1314-1320 | PR:P19327 | denotes | 5-HT1A |
| T115 | 1314-1320 | Q64264 | denotes | 5-HT1A |
| T116 | 1314-1320 | Q98998 | denotes | 5-HT1A |
| T117 | 1314-1320 | PR:P28285 | denotes | 5-HT1A |
| T118 | 1314-1320 | P08908 | denotes | 5-HT1A |
| T119 | 1314-1329 | D044282 | denotes | 5-HT1A receptor |
| T120 | 1316-1319 | CVCL_4W51 | denotes | HT1 |
| T122 | 1321-1336 | D044263 | denotes | receptor (5-HT1 |
| T127 | 1333-1336 | PR:Q2MHE4 | denotes | HT1 |
| T126 | 1333-1336 | CVCL_4W51 | denotes | HT1 |
| T128 | 1367-1372 | GO:0007568 | denotes | aging |
| T129 | 1398-1409 | UBERON:0002421 | denotes | hippocampus |
| T130 | 1398-1409 | UBERON:0001954 | denotes | hippocampus |
| T131 | 1398-1409 | UBERON:0002961 | denotes | hippocampus |
| T132 | 1411-1419 | UBERON:0001876 | denotes | amygdala |
| T134 | 1425-1445 | UBERON:0002043 | denotes | dorsal raphe nucleus |
| T139 | 1438-1445 | GO:0005634 | denotes | nucleus |
| T137 | 1438-1445 | CHEBI:33252 | denotes | nucleus |
| T140 | 1485-1490 | CVCL_D261 | denotes | RN46A |
| T141 | 1507-1511 | CVCL_0321 | denotes | HT22 |
| T142 | 1530-1534 | CHEBI:28790 | denotes | 5-HT |
| T143 | 1530-1534 | D012701 | denotes | 5-HT |
| T144 | 1530-1534 | D012701 | denotes | 5-HT |
| T146 | 1532-1535 | PR:Q2MHE4 | denotes | HT1 |
| T145 | 1532-1535 | CVCL_4W51 | denotes | HT1 |
| T147 | 1589-1594 | PR:Q5S006 | denotes | LRRK2 |
| T148 | 1589-1594 | PR:000003033 | denotes | LRRK2 |
| T149 | 1589-1594 | PR:Q5S007 | denotes | LRRK2 |
| T150 | 1628-1633 | PR:Q5S006 | denotes | LRRK2 |
| T151 | 1628-1633 | PR:000003033 | denotes | LRRK2 |
| T152 | 1628-1633 | PR:Q5S007 | denotes | LRRK2 |
| T153 | 1634-1643 | CHEBI:35222 | denotes | inhibitor |
| T154 | 1644-1649 | PR:Q5S006 | denotes | LRRK2 |
| T155 | 1644-1649 | PR:000003033 | denotes | LRRK2 |
| T156 | 1644-1649 | PR:Q5S007 | denotes | LRRK2 |
| T157 | 1644-1654 | CHEBI:78413 | denotes | LRRK2-IN-1 |
| T158 | 1644-1654 | C582847 | denotes | LRRK2-IN-1 |
| T159 | 1644-1654 | C582847 | denotes | LRRK2-IN-1 |
| T160 | 1650-1654 | CVCL_W473 | denotes | IN-1 |
| T161 | 1666-1671 | PR:Q5S006 | denotes | LRRK2 |
| T162 | 1666-1671 | PR:000003033 | denotes | LRRK2 |
| T163 | 1666-1671 | PR:Q5S007 | denotes | LRRK2 |
| T164 | 1701-1705 | CHEBI:28790 | denotes | 5-HT |
| T165 | 1701-1705 | D012701 | denotes | 5-HT |
| T166 | 1701-1705 | D012701 | denotes | 5-HT |
| T168 | 1703-1706 | PR:Q2MHE4 | denotes | HT1 |
| T167 | 1703-1706 | CVCL_4W51 | denotes | HT1 |
| T169 | 1709-1722 | GO:0006351 | denotes | transcription |
| T170 | 1814-1824 | GO:0065007 | denotes | regulation |
| T171 | 1828-1832 | CHEBI:28790 | denotes | 5-HT |
| T172 | 1828-1832 | D012701 | denotes | 5-HT |
| T173 | 1828-1832 | D012701 | denotes | 5-HT |
| T175 | 1830-1833 | PR:Q2MHE4 | denotes | HT1 |
| T174 | 1830-1833 | CVCL_4W51 | denotes | HT1 |
| T176 | 1876-1886 | UBERON:0004704 | denotes | depression |
| T177 | 1927-1932 | PR:Q5S006 | denotes | LRRK2 |
| T178 | 1927-1932 | PR:000003033 | denotes | LRRK2 |
| T179 | 1927-1932 | PR:Q5S007 | denotes | LRRK2 |
| T184 | 1956-1975 | D010300 | denotes | Parkinson's disease |
| T185 | 1956-1975 | D010300 | denotes | Parkinson's disease |
| T190 | 2005-2031 | D019636 | denotes | neurodegenerative disorder |
| T191 | 2005-2031 | D019636 | denotes | neurodegenerative disorder |
| T193 | 2298-2305 | 6308 | denotes | leucine |
| T194 | 2298-2305 | SO:0001437 | denotes | leucine |
| T192 | 2298-2305 | CHEBI:15603 | denotes | leucine |
| T195 | 2298-2305 | D007930 | denotes | leucine |
| T196 | 2298-2305 | CHEBI:25017 | denotes | leucine |
| T197 | 2298-2305 | D007930 | denotes | leucine |
| T198 | 2311-2317 | SO:0001068 | denotes | repeat |
| T199 | 2328-2333 | PR:Q5S006 | denotes | LRRK2 |
| T200 | 2328-2333 | PR:000003033 | denotes | LRRK2 |
| T201 | 2328-2333 | PR:Q5S007 | denotes | LRRK2 |
| T202 | 2355-2363 | SO:0000109 | denotes | mutation |
| T203 | 2395-2405 | UBERON:0004704 | denotes | depression |
| T207 | 2450-2456 | Q9N297 | denotes | 5-HT1A |
| T208 | 2450-2456 | Q0EAB6 | denotes | 5-HT1A |
| T209 | 2450-2456 | PR:000001161 | denotes | 5-HT1A |
| T210 | 2450-2456 | Q6XXX9 | denotes | 5-HT1A |
| T211 | 2450-2456 | Q9N296 | denotes | 5-HT1A |
| T212 | 2450-2456 | Q6XXY0 | denotes | 5-HT1A |
| T213 | 2450-2456 | P19327 | denotes | 5-HT1A |
| T214 | 2450-2456 | Q9N298 | denotes | 5-HT1A |
| T215 | 2450-2456 | PR:P19327 | denotes | 5-HT1A |
| T216 | 2450-2456 | Q64264 | denotes | 5-HT1A |
| T217 | 2450-2456 | Q98998 | denotes | 5-HT1A |
| T218 | 2450-2456 | PR:P28285 | denotes | 5-HT1A |
| T219 | 2450-2456 | P08908 | denotes | 5-HT1A |
| T220 | 2450-2465 | D044282 | denotes | 5-HT1A receptor |
| T221 | 2452-2455 | CVCL_4W51 | denotes | HT1 |
| T223 | 2486-2497 | UBERON:0002421 | denotes | hippocampus |
| T224 | 2486-2497 | UBERON:0001954 | denotes | hippocampus |
| T225 | 2486-2497 | UBERON:0002961 | denotes | hippocampus |
| T226 | 2499-2507 | UBERON:0001876 | denotes | amygdala |
| T228 | 2513-2533 | UBERON:0002043 | denotes | dorsal raphe nucleus |
| T233 | 2526-2533 | GO:0005634 | denotes | nucleus |
| T231 | 2526-2533 | CHEBI:33252 | denotes | nucleus |
| T234 | 2574-2579 | PR:Q5S006 | denotes | LRRK2 |
| T235 | 2574-2579 | PR:000003033 | denotes | LRRK2 |
| T236 | 2574-2579 | PR:Q5S007 | denotes | LRRK2 |
| T237 | 2693-2698 | PR:Q5S006 | denotes | LRRK2 |
| T238 | 2693-2698 | PR:000003033 | denotes | LRRK2 |
| T239 | 2693-2698 | PR:Q5S007 | denotes | LRRK2 |
| T240 | 2699-2707 | SO:0000109 | denotes | mutation |
| T244 | 2744-2750 | Q9N297 | denotes | 5-HT1A |
| T245 | 2744-2750 | Q0EAB6 | denotes | 5-HT1A |
| T246 | 2744-2750 | PR:000001161 | denotes | 5-HT1A |
| T247 | 2744-2750 | Q6XXX9 | denotes | 5-HT1A |
| T248 | 2744-2750 | Q9N296 | denotes | 5-HT1A |
| T249 | 2744-2750 | Q6XXY0 | denotes | 5-HT1A |
| T250 | 2744-2750 | P19327 | denotes | 5-HT1A |
| T251 | 2744-2750 | Q9N298 | denotes | 5-HT1A |
| T252 | 2744-2750 | PR:P19327 | denotes | 5-HT1A |
| T253 | 2744-2750 | Q64264 | denotes | 5-HT1A |
| T254 | 2744-2750 | Q98998 | denotes | 5-HT1A |
| T255 | 2744-2750 | PR:P28285 | denotes | 5-HT1A |
| T256 | 2744-2750 | P08908 | denotes | 5-HT1A |
| T257 | 2744-2759 | D044282 | denotes | 5-HT1A receptor |
| T258 | 2746-2749 | CVCL_4W51 | denotes | HT1 |
| T260 | 2800-2805 | CHEBI:23888 | denotes | drugs |
| T261 | 2824-2834 | UBERON:0004704 | denotes | depression |
PubMed_ArguminSci
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 145-256 | DRI_Approach | denotes | in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of Parkinson's disease (PD). |
| T2 | 257-278 | DRI_Challenge | denotes | The neuropathology of |
| T3 | 302-422 | DRI_Challenge | denotes | PD, including increased dopaminergic neurodegeneration and Lewy bodies, is indistinguishable from that of idiopathic PD. |
| T4 | 423-456 | DRI_Outcome | denotes | The subtle nonmotor phenotypes of |
| T5 | 480-513 | DRI_Outcome | denotes | PD have not been fully evaluated. |
| T6 | 514-685 | DRI_Outcome | denotes | In the present study, we examined anxiety/depression-like behaviors and accompanying neurochemical changes in differently aged transgenic (Tg) mice expressing human mutant |
| T7 | 698-699 | DRI_Outcome | denotes | . |
| T8 | 700-994 | DRI_Outcome | denotes | Through multiple behavioral tests, including light-dark test, elevated plus maze, sucrose preference test, forced swimming test, and tail-suspension test, we found that anxiety/depression-like behavior appeared in middle-aged (43-52 weeks) Tg mice before the onset of PD-like motor dysfunction. |
| T9 | 995-1157 | DRI_Background | denotes | These behavioral tests were performed using both male and female mice, and there were no sex-related differences in behavioral changes in the middle-aged Tg mice. |
| T10 | 1158-1264 | DRI_Background | denotes | Along with behavioral changes, serotonin levels also significantly declined in the hippocampus of Tg mice. |
| T11 | 1265-1446 | DRI_Outcome | denotes | Additionally, increases in the expression of the 5-HT1A receptor (5-HT1AR) grew more significant with aging and were detected in the hippocampus, amygdala, and dorsal raphe nucleus. |
| T12 | 1447-1588 | DRI_Background | denotes | In vitro study using the serotonergic RN46A and hippocampal HT22 cells showed that 5-HT1AR upregulation was related to enhanced expression of |
| T13 | 1602-1655 | DRI_Background | denotes | and was attenuated by the LRRK2 inhibitor LRRK2-IN-1. |
| T14 | 1656-1723 | DRI_Approach | denotes | Wild-type LRRK2 had no significant effect on 5-HT1AR transcription. |
| T15 | 1724-2083 | DRI_Challenge | denotes | The present study provides the first in vivo and in vitro evidence demonstrating abnormal regulation of 5-HT1AR along with the manifestation of anxiety/depression-like, nonmotor symptom in PD related to LRRK2.SIGNIFICANCE STATEMENT Parkinson's disease (PD), the second most common neurodegenerative disorder, is clinically characterized by motor dysfunctions. |
| T16 | 2084-2254 | DRI_Challenge | denotes | In most cases, various nonmotor symptoms present several years before the onset of the classical motor features of PD and severely affect the quality of life of patients. |
| T17 | 2255-2421 | DRI_Approach | denotes | Here, we demonstrate the causative role of leucine-rich repeat kinase 2 (LRRK2), a common PD-linked mutation, in the development of anxiety/depression-like behaviors. |
| T18 | 2422-2597 | DRI_Outcome | denotes | We found that age-dependent 5-HT1A receptor upregulation in the hippocampus, amygdala, and dorsal raphe nucleus is accompanied by the expression of the LRRK2 mutant phenotype. |
| T19 | 2598-2835 | DRI_Outcome | denotes | Our findings demonstrating a potential mechanism for nonmotor psychiatric symptoms produced by LRRK2 mutation suggest that directly targeting the 5-HT1A receptor can improve the therapeutic efficacy of drugs for PD-associated depression. |